What was studied?
The trials enrolled adults with moderate-to-severe obstructive sleep apnea and obesity. One studied participants without positive airway pressure at baseline; the other included participants receiving it.
What did the researchers report?
At 52 weeks, tirzepatide groups had larger reductions in the apnea-hypopnea index than placebo groups, alongside changes in weight and other measures. Gastrointestinal adverse events were common.
What are the limits?
These selected populations and monitored conditions matter. The findings are not instructions to stop an existing sleep-apnea treatment and do not establish effects in people without obesity.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.